12:00 AM
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MA09-hRPE cells: Phase I/II ongoing

Advanced Cell Technology said an independent DSMB recommended continuation of enrollment in the third cohort in an open-label, dose-escalation, U.S. Phase I/II trial evaluating sub-retinal transplantation of 50,000, 100,000, 150,000 and 200,000 RPE cells following an interim...

Read the full 161 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >